Les traitements par ARN interférents et par oligonucléotides antisens actuellement disponibles en France : une mise au point()

The arrival of anti-Covid-19 RNA vaccines in 2020 should not obscure the fact that for several years we have already had treatments based on interfering RNA or antisense oligonucleotides in a number of rare diseases with a very poor prognosis such as transthyretin amyloidosis, acute hepatic porphyri...

Descripción completa

Detalles Bibliográficos
Autor principal: Bouvenot, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: l'Académie nationale de médecine. Published by Elsevier Masson SAS. 2022
Materias:
Article Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851873/
https://www.ncbi.nlm.nih.gov/pubmed/35194225
http://dx.doi.org/10.1016/j.banm.2022.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851873/
https://www.ncbi.nlm.nih.gov/pubmed/35194225
http://dx.doi.org/10.1016/j.banm.2022.02.005

Ejemplares similares